New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

Researchers still don’t fully understand the cause of multiple sclerosis or why the rate of progression is so difficult to ...

Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing ...